为已有有效治疗方法的毒物开发新解毒剂:对乙酰氨基酚中毒中福美吡唑的案例研究
对乙酰氨基酚中毒唯一有效且获批的解毒剂是乙酰半胱氨酸,但中毒后8–12小时延迟治疗会降低疗效,且高危摄入时是否需增加剂量尚不确定。历史上乙酰半胱氨酸未经安慰剂对照研究,绝对获益未知,也从未进行患者剂量范围研究;西咪替丁的例子说明在小样本中度中毒患者中评估额外解毒剂疗效的弱点。当前监管机构要求的药物开发路径包括:在实验室模型中寻找明确治疗靶点、进行「原理验证」研究证明靶点可成药、在人体中确认原理验证,最后进行有足够把握度的匹配患者对照试验,此类研究费用高昂且非商业团体面临无资助风险。福美吡唑在小鼠中通过抑制细胞色素P4502E1和c-Jun N末端激酶预防对乙酰氨基酚诱导的肝毒性,但人类疗效证据仅基于无对照的小病例系列;作者结论认为对乙酰氨基酚中毒常见且随机对照试验可行,福美吡唑的获益只能通过此类研究证明,美国正在招募福美吡唑作为乙酰半胱氨酸附加治疗的临床试验,应得到全体临床毒理学家的支持,试验期间应劝阻期刊发表福美吡唑的小病例系列。
要点
- 乙酰半胱氨酸是对乙酰氨基酚中毒唯一有效且获批的疗法,但中毒后8–12小时延迟治疗会失效,且高危摄入是否需增加剂量尚不确定。
- 福美吡唑预防对乙酰氨基酚诱导肝毒性的证据仅来自无对照的小病例系列,其人类获益只能通过随机对照试验证明。
- 美国正在招募福美吡唑作为乙酰半胱氨酸附加治疗的临床试验,作者呼吁全体临床毒理学家支持该试验。
- 作者建议在试验进行期间,期刊应劝阻发表福美吡唑的小病例系列。
- 当前监管机构要求的药物开发路径包括实验室靶点识别、原理验证、人体确认和足够把握度的匹配患者对照试验,非商业团体面临资助风险。
适用人群与场景
- 对乙酰氨基酚中毒患者,包括中毒后8–12小时内未接受乙酰半胱氨酸治疗者,以及高危对乙酰氨基酚摄入者(原文讨论是否需增加乙酰半胱氨酸剂量的人群)
研究设计与关键结果
- 综述指出:乙酰半胱氨酸从未进行安慰剂对照研究,美国食品药品监督管理局亦未要求,因为当时认为高对乙酰氨基酚浓度的毒性如此明显,安慰剂对照研究不符合伦理,因此乙酰半胱氨酸的绝对获益仍未知。
- 综述指出:从未在患者中进行乙酰半胱氨酸的剂量范围研究。
- 综述指出:西咪替丁在对乙酰氨基酚中毒中的使用说明了在小样本中度中毒患者中评估额外解毒剂疗效的弱点。
- 综述指出:当前监管机构要求的药物开发路径包括:在实验室模型中寻找明确治疗靶点;进行「原理验证」研究证明靶点可成药;在人体中确认原理验证;最后进行有足够把握度的匹配患者对照试验以证明临床结局。
- 综述指出:福美吡唑在小鼠中通过抑制细胞色素P4502E1预防对乙酰氨基酚诱导的肝毒性,从而阻止对乙酰氨基酚转化为毒性代谢物;福美吡唑还抑制c-Jun N末端激酶,这是线粒体下游毒性的关键通路。
- 综述指出:福美吡唑在人类中的疗效证据基于无对照的小病例系列;已获批的适应症促进了福美吡唑在未经证实的适应症中的超说明书使用。
- 综述结论:对乙酰氨基酚中毒常见,随机对照临床试验可行;福美吡唑的获益只能通过此类研究证明;美国正在招募福美吡唑作为乙酰半胱氨酸附加治疗的临床试验,应得到全体临床毒理学家支持;在此期间,期刊应劝阻发表使用福美吡唑的小病例系列。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:对乙酰氨基酚中毒常见且随机对照试验可行,福美吡唑的获益只能通过随机对照试验证明。
- 作者呼吁:美国正在招募的福美吡唑作为乙酰半胱氨酸附加治疗的临床试验应得到全体临床毒理学家支持。
- 作者建议:在试验进行期间,期刊应劝阻发表福美吡唑的小病例系列。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Acetylcysteine is the only effective and licensed therapy for paracetamol poisoning. However, acetylcysteine loses efficacy if treatment is delayed 8-12 hours after paracetamol ingestion, and there is also uncertainty as to whether the dose should be increased in high-risk paracetamol ingestions. Studies have identified potential therapeutic targets, including enzymes that metabolize paracetamol; the pathways causing mitochondrial toxicity via c-Jun N-terminal kinases or superoxide generation; and other specific targets, such as nuclear factor-erythroid factor 2-dependent gene induction and autophagy. With this range of potential additional therapies, how should the speciality of clinical toxicology approach the development of new antidotes for this common poisoning?
HISTORICAL BACKGROUND: When the first treatments for paracetamol toxicity were developed, the clinical trial and ethical basis of practice were different from today. Acetylcysteine was never subjected to placebo-controlled studies, even by the United States Food and Drug Administration, as it was presumed that the toxicity of high paracetamol concentrations was so evident that placebo-controlled studies were unethical. Thus, the absolute benefit of acetylcysteine remains unknown. In addition, no dose-ranging studies of acetylcysteine in patients were ever done. The weakness of assessing the efficacy of additional antidotes in small groups of patients with moderate poisoning is illustrated by the use of cimetidine in paracetamol poisoning.
CURRENT APPROACHES TO DRUG (AND ANTIDOTE) DEVELOPMENT: The approach required by regulatory authorities today relies on several important steps. First, a clear target for therapeutic effect is sought, normally in a laboratory model. Next, a 'proof of principle' study is required to demonstrate that the target is 'druggable'. Finally, clinical studies to confirm proof of principle applies in humans, followed by a controlled trial with matched patient groups with sufficient power to demonstrate the clinical outcome being sought. Such patient studies can be expensive to conduct, and non-commercial groups suffer the risk of not being funded.
FOMEPIZOLE: Fomepizole prevents paracetamol-induced hepatic toxicity in mice by inhibiting cytochrome P4502E1, thereby preventing the conversion of paracetamol to its toxic metabolite. Fomepizole also inhibits c-Jun N-terminal kinases, a key pathway in the downstream toxicity on the mitochondria. The present evidence of efficacy in humans is based on small case series with no control groups. The availability of a licensed indication has facilitated off-label use of fomepizole in an unproven indication.
CONCLUSIONS: Paracetamol poisoning is common, and randomized, controlled clinical trials are possible. The benefit of fomepizole can only be shown by such a study. As clinical trials using fomepizole as an added therapy to acetylcysteine are recruiting in the United States, these should be supported by all clinical toxicologists. In the interim, the publication of small case series using fomepizole should be discouraged by journals.
参考来源
- Dear JW, Bateman DN. Developing new antidotes for poisons with existing effective treatments: a case study of fomepizole in paracetamol poisoning. Clin Toxicol (Phila). 2023. PMID: 37747339. doi:10.1080/15563650.2023.2259085
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。